Citizens Maintains Market Outperform on Microbot Medical, Lowers Price Target to $2
Citizens analyst Daniel Stauder maintains Microbot Medical (NASDAQ:MBOT) with a Market Outperform and lowers the price target from $2.5 to $2.
Follow the latest Microbot Medical, Inc. (MBOT) news and market headlines alongside the live MBOT price. Stay informed on what's moving MBOT.
Citizens analyst Daniel Stauder maintains Microbot Medical (NASDAQ:MBOT) with a Market Outperform and lowers the price target from $2.5 to $2.
Gainers Akanda (NASDAQ:AKAN) stock rose 42.6% to $1.94 during Monday's regular session. The market value of their outstanding shares is at $3.5 million. CEL-SCI (AMEX:CVM) shares increased by 30.46% to $1.67. The
U.S. stocks fell Monday as tech slid and manufacturing sentiment weakened; oil, gold and silver also declined, while TELUS and H World surged.
U.S. stocks fell, led by a 1.1% Nasdaq drop; tech slid while staples rose. Tyson beat estimates, and small-cap movers saw sharp gains and losses.
Microbot Medical (NASDAQ:MBOT) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 28.57 percent decrease over losses of $(0.07) per share
Gainers Akanda (NASDAQ:AKAN) shares increased by 55.1% to $2.11 during Monday's pre-market session. The market value of their outstanding shares is at $3.5 million. Alpha Tau Medical (NASDAQ:DRTS) stock rose
Take-Two rose 4% ahead of GTA VI’s Nov. 19 release on strong presales. GreenPower led gainers, while Datavault AI plunged 43%.
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to MBOT, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.